In this study, patients with stage III colon cancer received, after surgery, either an oral drug called capecitabine together with oxaliplatin (the XELOX regimen) or standard chemotherapy with fluorouracil and folinic acid. The chance of the disease coming back, a new colon cancer developing, or death was lower in the XELOX group. The difference in overall survival between the two groups was not statistically significant. The best regimen should be chosen with the advice of your treating doctor.
Colorectal cancer (adjuvant and metastatic), gastric cancer
| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Oxaliplatin | 130 mg/m² | IV over 2 hours | Day 1 |
| Capecitabine | 1000 mg/m² twice a day | Oral, within 30 minutes after food | Evening of day 1 to morning of day 15 |
Doses as in the NO16968 study.
On the page “CAPOX (XELOX): dose, schedule and side effects”
Advanced HER2-negative gastric cancer
| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Nivolumab | 360 mg | IV | Day 1 |
| Oxaliplatin | 130 mg/m² | IV | Day 1 |
| Capecitabine | 1000 mg/m² twice a day | Oral | Days 1 to 14 |
As in CheckMate 649.
Dose source:.
On the page “Nivolumab with CAPOX or FOLFOX in gastric cancer (CheckMate 649)”
Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.
Oxaliplatin 130 mg/m² on day 1 plus capecitabine 1,000 mg/m² twice daily on days 1 to 14 every 3 weeks, for 24 weeks. Number of patients: 944.
Standard adjuvant bolus fluorouracil and folinic acid regimen: the Mayo Clinic protocol for 24 weeks (664 patients; as this regimen is described in the FDA label for capecitabine: fluorouracil 425 mg/m² and leucovorin 20 mg/m² IV days 1 to 5 every 28 days, 6 cycles) or the Roswell Park protocol for 32 weeks (278 patients; dose not stated in the available sources). Total number of patients: 942.
Source of the regimen details: Abstract of the paper (XELOX doses); Mayo Clinic regimen dose from the FDA label for capecitabine (X-ACT section, the same standard regimen); the Roswell Park regimen dose is not stated in the available sources
Doses are given for the information of specialists, as in this study’s protocol, and are not a prescription. Every drug must be prescribed by the treating physician for the individual patient.
Patients with stage III colon cancer who had undergone surgery with curative intent (complete resection).
Primary endpoint: disease-free survival (DFS). The abstract also reports overall survival (OS).
Safety and adverse event data are not reported in the abstract; for grade 3 or higher adverse events, consult the full text.
Based on the abstract, XELOX improved disease-free survival compared with bolus FU/FA in stage III colon cancer and was presented as an additional adjuvant treatment option. The improvement in overall survival was not statistically significant. The status of this regimen in current clinical guidelines and drug approvals should be checked separately.
The control group received a bolus FU/FA regimen. The difference in overall survival was not statistically significant, and follow-up was ongoing at publication. Safety data are not given in the abstract.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.
Who are you reading this site as?
Your choice applies to every page; change it any time from the bottom of the page.
Type to search...